Pfizer has reported three cases of severe muscle weakness, two of which involved myocarditis, in its Phase 3 gene therapy trial in Duchenne muscular dystrophy (DMD).
This follows reporting by Solid Biosciences in May that it had seen inflammatory responses in its Phase 1/2 gene therapy trial in DMD.
Both therapies use AAV 9 vectors.
EvaluatePharma observes that “another gene therapy scare cannot be good for patient confidence overall.”
https://www.evaluate.com/vantage/articles/news/policy-and-regulation/pfizer-adds-gene-therapy-woes
https://hotcopper.com.au/threads/an...4830079/page-25?post_id=39332272#.YVZ-LpoRWUk
https://investors.solidbio.com/news...s-provides-first-quarter-2021-business-update
Ann: Annual Report to shareholders, page-17
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.5¢ | $142.7K | 751.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 204334 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 345272 | 11 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |